Adeno-Associated Virus Vectors in Gene Therapy
Author Information
Author(s): Coura Renata dos Santos, Nardi Nance Beyer
Primary Institution: Universidade Federal do Rio Grande do Sul
Conclusion
AAV-based vectors are generally safe and effective for gene transfer, but improvements in transduction efficiency are needed for better organ-specific expression.
Supporting Evidence
- AAV has been used in gene therapy since the first infectious clone was established in 1982.
- 85% of the available PubMed references on AAV were published in the last decade.
- AAV vectors have a broad host and cell type tropism range.
- AAV vectors maintain high levels of gene expression in vivo over several years.
- Recombinant AAV vectors are increasingly becoming the vector of choice for gene therapy.
Takeaway
AAV vectors are like tiny delivery trucks that can carry genes into cells without causing harm, but sometimes they don't deliver enough genes to the right places.
Methodology
This review summarizes the advances in AAV vector technology and their applications in gene therapy.
Potential Biases
There is a potential risk of tumorigenesis associated with AAV2 vector gene transfer.
Limitations
AAV vectors have size limitations for gene insertion and slow onset of gene expression.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website